MedTrace Logo

Effect of Inhaled Albuterol in Pulmonary Hypertension

NCT03270332 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-30

Study results available
· View outcomes & findings →

Summary

The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Albuterol

inhalation of 270μg albuterol through a spacer

DRUG

Placebo

inhalation of placebo through a spacer

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Adam Wanner, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-05
Primary Completion
2020-07-02
Completion
2020-07-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03270332 on ClinicalTrials.gov